Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | SOLO-1: practice changing results for advanced ovarian cancer

SOLO-1 (NCT01844986) is the first Phase III study of a maintenance PARP inhibitor in the frontline setting in advanced ovarian cancer. Susana Banerjee, MBBS, PhD, FRCP, from the Royal Marsden NHS Foundation Trust, London, UK, describes the practice changing results from this study, presented at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Patients with BRCA mutated ovarian cancer who had previously received first-line platinum-based chemotherapy were given olaparib as a monotherapy. These women had a clinically significant benefit with regards to overall survival.